[Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study]. / Bevacizumab en association à une première ligne de chimiothérapie chez des patients atteints d'un cancer bronchique non à petites cellules, non épidermoïde, à un stade avancé ou en rechute : résultats de l'étude non interventionnelle EOLE.
Rev Mal Respir
; 34(1): 36-43, 2017 Jan.
Article
in Fr
| MEDLINE
| ID: mdl-27266900
ABSTRACT
INTRODUCTION:
The EOLE cohort aimed to describe, in routine clinical practice, the characteristics and management of patients receiving bevacizumab in combination with first-line metastatic chemotherapy for advanced metastatic or recurrent non squamous non-small cell lung cancer (nsNSCLC), as well as its efficacy and safety.METHODS:
A total of 423 patients were enrolled in this prospective, national, multicenter study. Data were collected every 3 months over an 18-month period.RESULTS:
Amongst the 407 patients analyzed (mean age 60±10 years, male 68%, ECOG-PS≤1 88%, smokers or former smokers 87%, cardiovascular comorbidities 40%), all except for 2 patients received bevacizumab (7.5 or 15mg/kg/3 weeks in 99% of patients) in combination with doublet chemotherapy. A total of 160 (60%) patients who completed induction received bevacizumab maintenance therapy. Median progression-free survival was 6.9 months (95% CI=[6.0-7.5]). Median overall survival (12.8 months [10.4-14.7]) was longer in patients with ECOG-PS≤1 (14.4 months [12.3-15.9] versus 4.9 months [3.4-8.3] if ECOG-PS=2). A total of 131 (32%) patients experienced at least one serious adverse event (SAE), and 51 (12%) at least one bevacizumab-related SAE.CONCLUSION:
EOLE confirms the efficacy and safety of bevacizumab in aNSCLC patients, in current medical practice.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Angiogenesis Inhibitors
/
Bevacizumab
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
Fr
Journal:
Rev Mal Respir
Year:
2017
Document type:
Article